Viral Related Tools Against SARS-CoV-2

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2020 Oct 21

PMID 33081350

Citations 2

Authors

Laura Fernandez-Garcia

Olga Pacios

Monica Gonzalez-Bardanca

Lucia Blasco

Ines Bleriot

Anton Ambroa

Maria Lopez

German Bou

Maria Tomas

Affiliations

Soon will be listed here.

Abstract

At the end of 2019, a new disease appeared and spread all over the world, the COVID-19, produced by the coronavirus SARS-CoV-2. As a consequence of this worldwide health crisis, the scientific community began to redirect their knowledge and resources to fight against it. Here we summarize the recent research on viruses employed as therapy and diagnostic of COVID-19: (i) viral-vector vaccines both in clinical trials and pre-clinical phases; (ii) the use of bacteriophages to find antibodies specific to this virus and some studies of how to use the bacteriophages themselves as a treatment against viral diseases; and finally, (iii) the use of CRISPR-Cas technology both to obtain a fast precise diagnose of the patient and also the possible use of this technology as a cure.

Citing Articles

An Overview of the Application of Viruses to Biotechnology.

Varanda C, Felix M, Campos M, Materatski P Viruses. 2021; 13(10).

PMID: 34696503 PMC: 8541484. DOI: 10.3390/v13102073.

Discovery of Antivirals Using Phage Display.

Sokullu E, Gauthier M, Coulombe B Viruses. 2021; 13(6).

PMID: 34200959 PMC: 8230593. DOI: 10.3390/v13061120.

References

Ren X, Liu B, Yin J, Zhang H, Li G . Phage displayed peptides recognizing porcine aminopeptidase N inhibit transmissible gastroenteritis coronavirus infection in vitro. Virology. 2010; 410(2):299-306. PMC: 7111919. DOI: 10.1016/j.virol.2010.11.014. View

Blasco L, Ambroa A, Trastoy R, Bleriot I, Moscoso M, Fernandez-Garcia L . In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Sci Rep. 2020; 10(1):7163. PMC: 7188820. DOI: 10.1038/s41598-020-64145-7. View

Sun J, Zhuang Z, Zheng J, Li K, Wong R, Liu D . Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. 2020; 182(3):734-743.e5. PMC: 7284240. DOI: 10.1016/j.cell.2020.06.010. View

Bastos M, Tavaziva G, Abidi S, Campbell J, Haraoui L, Johnston J . Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020; 370:m2516. PMC: 7327913. DOI: 10.1136/bmj.m2516. View

Carter B . Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 2005; 16(5):541-50. DOI: 10.1089/hum.2005.16.541. View

Twort F . Further Investigations on the Nature of Ultra-Microscopic Viruses and their Cultivation. J Hyg (Lond). 2010; 36(2):204-35. PMC: 2170983. DOI: 10.1017/s0022172400043606. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871):1021-8. PMC: 5424647. DOI: 10.1016/S0140-6736(13)60177-4. View

10.

Citorik R, Mimee M, Lu T . Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014; 32(11):1141-5. PMC: 4237163. DOI: 10.1038/nbt.3011. View

11.

Chan W, Rahman M, McFadden G . Oncolytic myxoma virus: the path to clinic. Vaccine. 2013; 31(39):4252-8. PMC: 3755036. DOI: 10.1016/j.vaccine.2013.05.056. View

12.

Duan J, Yan X, Guo X, Cao W, Han W, Qi C . A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun. 2005; 333(1):186-93. PMC: 7092839. DOI: 10.1016/j.bbrc.2005.05.089. View

13.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

14.

Kang X, Yang B, Hu Y, Zhao H, Xiong W, Yang Y . Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display. Clin Vaccine Immunol. 2006; 13(8):953-7. PMC: 1539127. DOI: 10.1128/CVI.00037-06. View

15.

Li Y, Li S, Wang J, Liu G . CRISPR/Cas Systems towards Next-Generation Biosensing. Trends Biotechnol. 2019; 37(7):730-743. DOI: 10.1016/j.tibtech.2018.12.005. View

16.

van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham J, Port J . ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020; 586(7830):578-582. PMC: 8436420. DOI: 10.1038/s41586-020-2608-y. View

17.

De Clercq E . New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019; 14(22):3962-3968. PMC: 7159701. DOI: 10.1002/asia.201900841. View

18.

Deveau H, Barrangou R, Garneau J, Labonte J, Fremaux C, Boyaval P . Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol. 2007; 190(4):1390-400. PMC: 2238228. DOI: 10.1128/JB.01412-07. View

19.

Wold W, Toth K . Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013; 13(6):421-33. PMC: 4507798. DOI: 10.2174/1566523213666131125095046. View

20.

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View